Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | CKS1B | P61024 | 1/20 | 0.34 |
| ▸ | SKP1 | P63208 | 1/20 | 0.34 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NCF1 | P14598 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4269575 | 0.82 | CKS1B (0.40) | CYP11B1CYP11B2CKS1BSKP1SKP2 | |
| SCHEMBL9458957 | 0.76 | CYP11B1 (0.35) | CYP11B1CYP11B2CKS1BSKP1SKP2 | |
| SCHEMBL29571645 | 0.74 | JAK3 (0.36) | — | |
| SCHEMBL240351 | 0.73 | MEN1 (0.40) | CYP11B1CYP11B2CKS1BSKP1SKP2 | |
| SCHEMBL15306565 | 0.73 | CYP11B1 (0.33) | CYP11B1CYP11B2CKS1BSKP1SKP2 | |
| SCHEMBL31273538 | 0.73 | — | — | |
| SCHEMBL4968 | 0.73 | — | — | |
| SCHEMBL29361363 | 0.72 | KCNQ3 (0.35) | — | |
| SCHEMBL11462712 | 0.71 | CDK2 (0.44) | CYP11B1CYP11B2CKS1BSKP1SKP2 | |
| SCHEMBL15133517 | 0.71 | CDK2 (0.44) | CYP11B1CYP11B2CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11261200-B2 | Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2022-03-01 | — | — | US | disclosed |
| EP-3512837-B1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2020-07-22 | — | — | EP | disclosed |
| EP-3512837-B1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2020-07-22 | — | — | EP | disclosed |
| US-20190276478-A1 | HETEROARYLTRIFLUOROBORATE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC | 2019-09-12 | — | — | US | disclosed |
| US-20190276478-A1 | HETEROARYLTRIFLUOROBORATE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC | 2019-09-12 | — | — | US | disclosed |
| EP-3522892-A2 | HETEROARYLTRIFLUOROBORATE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | The Global Alliance for TB Drug Development, Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3512837-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | Boehringer Ingelheim International GmbH (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-10138222-B2 | Substituted benzamides as RIPK2 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-27 | — | — | US | disclosed |
| WO-2018067762-A2 | HETEROARYLTRIFLUOROBORATE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| WO-2018067762-A2 | HETEROARYLTRIFLUOROBORATE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| WO-2018052773-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018052773-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-22 | — | — | WO | disclosed |
| US-20180072703-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072703-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138222-B2 | Substituted benzamides as RIPK2 inhibitors | RIPK2, RIPK4, RIPK1 | CYP11B1 2521/4885CYP11B2 1804/4885CKS1B 237/4885 |
| US-11261200-B2 | Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections | FNTB, CYP2F1, SDHB | CYP11B1 55/4885CYP11B2 63/4885CKS1B 3159/4885 |
| US-20180072703-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | CYP11B1 1184/4885CYP11B2 856/4885CKS1B 568/4885 |
| US-20190276478-A1 | HETEROARYLTRIFLUOROBORATE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | FNTB, CYP2F1, SDHB | CYP11B1 55/4885CYP11B2 63/4885CKS1B 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.